RxDoctor Payments Data

Peter Marcus, MD

Family Medicine · Bronx, NYNPI 1881624997

Payments from drug & device makers

$773in general payments, 2019–2025

Across 32 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$116
  • Viiv Healthcare Company$115
  • Janssen Products, LP$99
  • Gilead$86
  • BD$70
  • Sunovion Pharmaceuticals Inc.$65
  • plus $221 from 7 others

What the payments were for

  • Speaking & faculty fees$709%
  • Food & beverage$60478%
  • Education$9913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$773 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$7,594
Medicare patients
39
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala142$561,164
TivicayDolutegravir Sodium82$181,311
JardianceEmpagliflozin192$147,368
DovatoDolutegravir Sodium/Lamivudine45$126,386
PrezcobixDarunavir/Cobicistat41$96,178
OdefseyEmtricitab/Rilpiviri/Tenof Ala26$90,944
OzempicSemaglutide74$80,690
DescovyEmtricitabine/Tenofov Alafenam35$75,303
JulucaDolutegravir/Rilpivirine19$71,264
TriumeqAbacavir/Dolutegravir/Lamivudi20$70,151
TrulicityDulaglutide52$67,090
EliquisApixaban93$61,360
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$44,715
RybelsusSemaglutide33$42,447
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$40,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$86$681,182189 claims
Viiv Healthcare CompanyTivicay, Dovato, Juluca, Triumeq$115$449,111166 claims
Johnson & JohnsonPrezcobix$116$96,17841 claims
Lilly USA, LLCTrulicity$15$67,09052 claims
AbbVieLinzess$63$21,96237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →